Abstract：Objective: To investigate the effect of rituximab on vision and intestinal flora in patients with neuromyelitis optica. Methods: A total of 127 patients with neuromyelitis optica admitted to our hospital from March 2018 to March 2021 were selected for research, and they were divided into a study group (n=64) and a control group (n=63) by a simple random method using a random number table. Both groups were given hormone pulse therapy in the acute phase, the study group was given rituximab therapy in the remission phase, and the control group was given cyclophosphamide intravenous infusion therapy in the remission phase. The Disability Status Scale (EDSS) was used to evaluate the treatment effect. The visual acuity and intestinal flora distribution before and after 8 weeks of treatment were compared between the two groups, and the incidence of adverse reactions during the treatment was compared. The study was followed up for 1 year to compare the recurrence of the two groups. Results: After treatment, the function of EDSS subitems in the two groups recovered significantly compared with that before treatment (P<0.05). The differences of cone system function, brain stem function, vesicorectal function and visual function scores in the study group before and after treatment were higher than those in the control group (P<0.05). The worst eye, the best eye and the average logMAR corrected visual acuity after treatment in the two groups. The difference before and after treatment in the study group was higher than that in the control group (P<0.05), and the recurrence rate was lower than that in the control group (P<0.05). After treatment, the Chaol index and Shannon index were (233.15±15.26) and (3.36±0.68), respectively, which were higher than those of the control group (P<0.05), and there was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: Rituximab has obvious effects on improving vision and intestinal flora structure in patients with neuromyelitis optica, and has the value of popularization and application.
李邦静, 陈睿, 王瑞. 利妥昔单抗对视神经脊髓炎患者视力及肠道菌群的影响分析[J]. 河北医学, 2023, 29(3): 507-511.
LI Bangjing, et al. Effects of Rituximab on Visual Acuity and Intestinal Flora in Patients with Neuromyelitis Optica. HeBei Med, 2023, 29(3): 507-511.
[1] Jin Y K,Oh H J,Kim Y,et al.Sporadic amyotrophic lateral sclerosis with seropositive neuromyelitis optica spectrum disorder:a case report[J].Medicine,2021,100(16):25580. [2] Paton D M.Satralizumab:an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders[J].Drugs of today (Barcelona,Spain:1998),2021,57(3):209. [3] Solomon J M,Paul F,Chien C,et al.A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course:[J].Therapeutic Advances in Neurological Disorders,2021,14(23):805-815. [4] Wang J Y,Chen X W,et al.Meningoenn cephalitis as an initial manifestation of neuromyelitis optica spetrum disorder[J].Mult Scler,2013,19(5):639-643. [5] 苗晓慧,石紫燕,陈虹西,等.视神经脊髓炎患者生活质量调查[C].第十一届全国免疫学学术大会. [6] 付俊霞,魏世辉.单克隆抗体在治疗视神经脊髓炎谱系疾病中的临床应用进展[J].中华眼底病杂志,2021,37(3):240-244. [7] 赵云菲,巫明慧,孟华星,等.靶向B细胞耗竭药物治疗视神经脊髓炎谱系疾病的研究进展[J].中西医结合心脑血管病杂志,2021,19(24):4309-4312. [8] 李园园,俞海,王笑竹,等.一项B细胞监测下减量利妥昔单抗治疗视神经脊髓炎谱系病的前瞻性研究[J].中风与神经疾病杂志,2021,38(4):345-348. [9] Kim S H,Jang H,Na Y P,et al.Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies[J].Neurology Neuroimmunology & Neuroinflammation,2021,8(2):947. [10] 陈星星,仓顺东.肠道微生物与免疫检查点阻断剂相互作用机制的研究进展[J].临床肿瘤学杂志,2020,25(4):374-377. [11] 赵丽,王佳伟.神经系统自身免疫性疾病与肠道微生物相关性的研究进展[J].中华预防医学杂志,2022,56(3):256-261.
2023, Vol. 29 
冀公网安备13080202000677号